Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Nat Med. Author manuscript; available in PMC 2010 August 1.
Published in final edited form as:
Published online 2009 June 21. doi:  10.1038/nm.1972
PMCID: PMC2859814

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation


HIV persists in a reservoir of latently infected CD4+ T cells in individuals treated with highly active antiretroviral therapy (HAART). Here we identify central memory (TCM) and transitional memory (TTM) CD4+ T cells as the major cellular reservoirs for HIV and find that viral persistence is ensured by two different mechanisms. HIV primarily persists in TCM cells in subjects showing reconstitution of the CD4+ compartment upon HAART. This reservoir is maintained through T cell survival and low-level antigen-driven proliferation and is slowly depleted with time. In contrast, proviral DNA is preferentially detected in TTM cells from aviremic individuals with low CD4+ counts and higher amounts of interleukin-7–mediated homeostatic proliferation, a mechanism that ensures the persistence of these cells. Our results suggest that viral eradication might be achieved through the combined use of strategic interventions targeting viral replication and, as in cancer, drugs that interfere with the self renewal and persistence of proliferating memory T cells.

Treatment of HIV infection has markedly reduced the death rate from AIDS and improved the quality of life of HIV-infected individuals1. However, complete eradication of HIV with antiretroviral drugs seems impossible, as the virus persists in cellular reservoirs2,3. The major HIV reservoir is a small pool of latently infected resting memory CD4+ T cells carrying an integrated form of the viral genome4,5 that lacks the ability to produce viral proteins6. CD4+ T cell depletion is associated with a larger viral reservoir size7, whereas early initiation of HAART is often associated with a reduced size of the HIV reservoir8 and the normalization of the CD4/CD8 ratio9. These observations suggest that CD4+ T cell depletion, which is directly associated with increased levels of CD4+ T cell proliferation10,11, may drive the size of the HIV reservoir by as yet unidentified mechanisms.

Two distinct mechanisms could contribute to the persistence of this reservoir. First, low levels of viral replication could lead to de novo infection of memory CD4+ T cells, ensuring the continuous replenishment of the HIV reservoir12,13. However, the absence of genetic evolution in viral reservoirs does not support this possibility1317. Moreover, plasma viral RNA sequences under HAART diverge from cell-associated viral DNA, providing further evidence that de novo infection of cells is unlikely to be implicated in the persistence of the reservoir18. The intrinsic stability of latently infected CD4+ T cells constitutes an alternative explanation for the stability of the reservoir, as TCM cells survive for years1921. Indeed, we have shown that prosurvival pathways are specifically triggered in TCM cells21,22, indicating that TCM cells may encompass the long-lived HIV reservoir. The differentiation of TCM cells into TEM cells is observed after T cell receptor (TCR) triggering23,24 and, to a lesser extent, in response to homeostatic cytokines such as interleukin-7 (IL-7) and IL-15 (ref. 25). The contribution of antigen-induced or homeostatic proliferation to the size and maintenance of the reservoir has yet to be defined. This is particularly relevant in the context of HAART, where high levels of immune activation, increased plasma concentrations of IL-7 and an increased percentage of cycling CD4+ T cells have been observed in individuals with low absolute CD4+ T cell counts26. Here we show the presence of two distinct HIV reservoirs: one in TCM cells, regulated by antigen-driven proliferation, and one in TTM cells, regulated by homeostatic proliferation.


HIV proviral DNA is detected in TCM and TTM cells

To identify the major molecular forms of HIV associated with its persistence, we measured levels of total DNA, integrated DNA and 2-LTR circles, which are labile intermediates in the virus life cycle, in CD4+ T cells from 14 successfully treated individuals, including four subjects from whom we obtained peripheral blood mononuclear cells (PBMCs) before and after initiation of HAART. The results indicated a rapid and profound drop in levels of 2-LTR circles upon initiation of HAART (Fig. 1a), whereas HIV proviral DNA was more stable than and present in similar amounts to total HIV DNA after prolonged HAART (Fig. 1b), confirming that the total HIV DNA found in CD4+T cells after prolonged virus suppression largely represents integrated HIV genomes, as recently reported27. These results identify integrated viral DNA as the major and most stable molecular form of HIV in CD4+ T cells from successfully treated subjects.

Figure 1
Integrated DNA is the major molecular form of HIV during HAART and is harbored by TCM and TTM cells in vivo. (a) Frequencies of total, integrated and 2-LTR circle DNA molecules in CD4+ T cells before and after HAART initiation. Molecular forms of HIV ...

To determine whether the stability of integrated viral DNA can be attributed to the persistence of specific memory CD4+ T cell compartments, we sorted CD4+ T cell subsets from 17 aviremic subjects (Supplementary Table 1) on the basis of surface expression of CD45RA, CC chemokine receptor-7 (CCR7) and CD27 and performed highly sensitive quantification of integrated HIV proviral DNA on the sorted subsets. On the basis of CD45RA and CCR7 expression, we identified various CD4+ subsets, including naive (TN), central memory (TCM) and terminally differentiated (TTD) cells (Supplementary Fig. 1a). CD27 expression allowed us to distinguish effector memory (TEM) cells from the transitional memory CD4+ T cell subset (TTM cells); the latter cells show functional and transcriptional characteristics that are intermediate between those of TCM cells and TEM cells21.

We determined the percentage of each cellular subset within the pool of CD4+ T cells from 31 aviremic individuals (Fig. 1c). The frequency of cells within each subset harboring HIV proviral DNA ranged from 0 to 10.2 × 103 copies of HIV provirus per 1 × 106 cells of a given subset (Fig. 1d and Supplementary Fig. 1b). Our results clearly indicate that the HIV reservoir constitutes cells harboring a memory phenotype (mean contributions of TCM cells and TTM and TEM cells of 51.7% and 46.6%, respectively), whereas TN cells and TTD cells marginally contribute to the pool of cells harboring HIV proviral DNA (mean contributions of 1.9% and 0.3%, respectively, Fig. 1e). Overall, the contributions of TCM cells and TTM cells to the HIV reservoir were higher than that of TEM cells (mean contributions of 51.7%, 34.3% and 13.9%, respectively). To confirm that CD4+ T cells harbor replication-competent virus, we sorted cells from each subset of four aviremic subjects and measured viral production after co-culture and stimulation with allogeneic dendritic cells and phytohemagglutinin-activated CD4+ T cells from HIV-negative donors (Supplementary Fig. 2). These results showed that CD4+ T cells subsets harboring HIV proviral DNA are able to produce infectious virus after stimulation.

We also measured the frequency of cells harboring HIV proviral DNA in lymph nodes and gut biopsies from successfully treated individuals (Supplementary Fig. 3a–f). We found that lymph nodes were enriched (fold enrichment of 2.4) for memory CD4+ T cells as compared to blood, but the frequencies of memory CD4+ T cells harboring proviral DNA were comparable in both compartments (means of 516 copies and 603 copies of HIV integrated DNA in 1 × 106 memory CD4+ T cells from PBMCs and lymph node mononuclear cells, respectively). We did the same quantifications in PBMCs and matched gut biopsies from eight subjects on HAART; the results showed that the frequencies of cells harboring HIV proviral DNA are similar and highly correlated between these two compartments (Supplementary Fig. 3f). Together, these experiments show that TCM, TTM and TEM cells contribute to various degrees to the HIV reservoir and can produce infectious viral particles upon activation. Moreover, experiments with PBMCs of individuals on HAART, aimed at quantifying proviral DNA, did indeed reflect the contribution of the lymphoid tissue environment to the HIV reservoir.

Absolute CD4+ count identifies the HIV reservoir

Our results also showed that the relative contributions of TCM and TTM cells to the pool of HIV-infected cells are highly variable from one subject to another (Fig. 1e). We observed that CD4/CD8 ratios >1, high nadir CD4+ count and initiation of HAART within the first year of HIV infection are strongly associated with an HIV reservoir of limited size (P < 0.0001, P < 0.0005 and P < 0.0001, respectively; Fig. 2a–c). As CD4+ T cell depletion was also associated with an increased HIV reservoir size (P = 0.03, Fig. 2d), we examined whether absolute CD4+ counts affect the reservoir localization in TCM and TTM cells. We found that TCM cells were underrepresented in subjects with low CD4+ counts, suggesting that TCM cells are selectively depleted or differentiated into TTM cells in these subjects (P = 0.02, Fig. 2e). Moreover, the frequency of infected TTM cells was higher in subjects with low CD4+ counts, whereas TCM cells were preferentially infected in subjects with high absolute CD4+ counts (P < 0.0001, Fig. 2f). As TCM cells were overrepresented and preferentially infected in individuals with high CD4+ counts, they constituted the major reservoir for HIV in those subjects (P = 0.004, Fig. 2g). Conversely, the HIV reservoir was mainly localized in TTM cells in individuals with low CD4+ counts (P = 0.006).

Figure 2
CD4+ T cell depletion drives the size and the localization of the HIV reservoir. (ad) Integrated HIV DNA copy number, as determined in the CD4+ T cells from 33 virally suppressed HIV-infected subjects by Alu real-time PCR. (a) Comparison of the ...

Immune activation identifies the HIV reservoir

Depletion of CD4+ T cells is associated with high levels of immune activation and increased proliferation of CD4+ T cells10,11,26. As we found that the absolute CD4+ count determines the size and the localization of the HIV reservoir, we examined the impact of the residual immune activation on these parameters. Absolute CD4+ counts were negatively correlated with the expression of the immune activation and proliferation marker Ki67 in CD4+ T cells (P = 0.007, Fig. 3a). Notably, high frequencies of Ki67+CD4+ T cells were associated with a larger size of the viral reservoir (P = 0.01, Fig. 3b), suggesting that T cell proliferation might provide a mechanism for the maintenance of the HIV reservoir. Moreover, we found that the levels of cellular proliferation could predict not only the size but also the localization of the HIV reservoir, as high levels of Ki67 protein expression were correlated with preferential infection of TTM cells (P = 0.008, Fig. 3c) and with a higher contribution of this subset to the HIV reservoir (P = 0.0006, Fig. 3d). Conversely, TCM cells were the main reservoir in individuals with limited levels of cellular proliferation (P = 0.002; Fig. 3d).

Figure 3
Proliferation of CD4+ T cells drives the size and the localization of the HIV reservoir. (a) Correlation between the absolute CD4+ count and the level of cellular proliferation, as measured by intracellular Ki67 expression in CD4+ T cells from 33 individuals ...

Together, these results indicate that low absolute CD4+ counts are associated with high levels of cellular proliferation and an increased size of an HIV reservoir mainly harbored by TTM cells. Conversely, we observed a viral reservoir of limited size mainly harbored by TCM cells in individuals with high absolute CD4+ counts and limited proliferation of CD4+ T cells.

TCM and TTM CD4+ T cells define distinct HIV reservoirs

We next characterized the phenotypes of TCM cells and TTM cells to determine whether their contribution to the HIV reservoir is a function of their proliferative status. TTM cells included higher frequencies of Ki67+ and PD-1+ cells than TCM cells but lower frequencies than TEM cells (Fig. 3e). Moreover, and irrespective of the phenotype of the CD4+ subset, the HIV reservoir was mainly composed of cells endowed with limited proliferation indexes (Ki67, P < 0.0001 and PD-1, P = 0.0002), confirming the quiescent nonactivated state of cells that constitute the HIV reservoir in HAART-treated subjects2 (Fig. 3f). Our results indicate that highly proliferating T cells such as TEM cells (range of Ki67+ cells, 3.4–10.9%) do not constitute a stable reservoir for HIV, which is consistent with their limited contribution to the pool of latently HIV-infected cells. In contrast, TCM cells and TTM cells are characterized by low to intermediate levels of proliferation and constitute the main viral reservoir. These results suggest a model in which HIV can persist in TCM and TTM cells by continuous low-level proliferation, ensuring the persistence of integrated viral DNA through mitosis. We thus sorted TCM cells and TTM cells from four HAART-treated subjects according to their PD-1 expression, a marker of homeostatic28,29 and antigen-induced30 proliferation, as indicated by the strong correlation between PD-1 and Ki67 expression in CD4+ T cells from HAART-treated individuals (P = 0.0002, Fig. 3g). Quantification of HIV proviral DNA in each fraction showed that PD-1hi cells were enriched for HIV proviral DNA when compared to the corresponding PD-1lo fractions (P = 0.016), confirming that proliferating TCM and TTM cells constitute a privileged cellular reservoir for HIV (Fig. 3h). These results indicate that HIV preferentially persists in TCM and TTM cells that proliferate at low levels.

The TTM cell reservoir is fueled by proliferating TCM cells

We amplified Env sequences from proviral DNA obtained from TCM cells and TTM cells of ten HAART-treated subjects and performed phylogenetic analyses to assess the interdependence of each cellular reservoir by comparing HIV sequences obtained from both cellular reservoirs (Fig. 4a). With the exception of three clones obtained from one subject, all viruses (n ¼ 427) were predicted to use CCR5; hence, co-receptor usage could not allow us to evidence the interdependence of the TCM and TTM reservoirs. However, sequences obtained from TCM cells and TTM cells of individuals that were good responders to HAART (see subject D as an example, CD4+Ki67+ 1.4%) did not cluster together, indicating that in those subjects these ¼ reservoirs are genetically independent (Fig. 4a). In contrast, in aviremic subjects characterized by higher levels of CD4+ T cell proliferation (for example, subject A, CD4+Ki67+ ¼ 3.5%), viral quasispecies were shared by TCM cells and TTM cells, as shown by the unique cluster of variants found in the neighbor-joining tree (Fig. 4a). When performed in ten subjects, the phylogenetic analysis confirmed that increased turnover of TTM cells is associated with a reduced HIV genetic distance measured between the two compartments (P = 0.0005, Fig. 4b), a consequence of the residual immune activation and cell proliferation leading to the differentiation of T cells into TCM cells into TCM cells10,11.

Figure 4
TCM and TTM cells define a distinct HIV reservoir. (a) Neighbor-joining trees derived from HIV sequences obtained from TCM cells and TTM cells of four representative HAART-treated HIV-infected subjects. TCM and TTM cells from ten aviremic subjects were ...

Cell proliferation ensures HIV reservoir stability

We determined the impact of cellular proliferation on the genetic diversity of proviral DNA within both cellular reservoirs. We did not find any association between the genetic diversity of the TCM reservoir and levels of TCM cell proliferation (Fig. 4c), indicating that TCM cells harboring archived proviral DNA constitute a stable reservoir with minimal proliferation levels, in agreement with their enhanced survival21. In contrast, proliferation of TTM cells was associated with a reduced HIV diversity in this subset (P = 0.001, Fig. 4c). This result suggested a mechanism by which HIV-infected TTM cells maintain the size and the lack of HIV genetic diversity of the viral reservoir by continuous self-renewal through the proliferation of a small number of cells. To verify this hypothesis, we performed a longitudinal analysis in five aviremic subjects from whom we obtained viral sequences at two time points separated by at least 14 months (Supplementary Table 2 and Supplementary Fig. 4). We aligned sequences obtained from TCM cells and TTM cells at these two time points and drew phylogenetic trees reflecting the evolution of viral sequences (Fig. 5a and Supplementary Fig. 5). To measure the genetic evolution of the HIV reservoir, we quantified the divergence as the average genetic distance between sequences from the two time points within each T cell subset (Fig. 5b). Our results indicated that high proliferation levels in TTM cells are associated with a limited genetic evolution of the reservoir over time, in agreement with a mechanism by which persistence of this reservoir is ensured by a small number of HIV-infected proliferating CD4+ T cells (subject A, Fig. 5a,b).

Figure 5
Proliferation of TTM cells is associated with a genetic stability of the HIV reservoir over time. (a) Neighbor-joining trees derived from HIV sequences obtained from TCM cells and TTM cells of two representative aviremic individuals at first and second ...

To our surprise, in subjects with low frequencies of Ki67+ cells, sequences obtained from the two time points did not cluster together (subject E, Fig. 5a,b). The apparent evolution of HIV sequences in individuals with high CD4+ T cell counts probably reflects the sampling of different archived sequences rather than a genetic evolution of the proviral populations. These sequences may be present at variable frequencies as a consequence of the proliferation and death of distinct T cell clones in subjects who are still endowed with a functional CD4+ compartment3133.

HIV reservoir is maintained by IL-7–mediated proliferation

CD4+ T cell depletion is directly correlated with high levels of plasma IL-7 (refs. 26,3436), a cytokine responsible for the survival and homeostatic proliferation of CD4+ T cells25,37,38. We observed higher amounts of IL-7 in the plasma of individuals with a high frequency of proliferating cells and limited evolution of the viral reservoir over time (Fig. 5b). We then assessed the role of this cytokine in the maintenance of the size of the reservoir. We determined the frequency of CD4+ T cells harboring proviral DNA in eight aviremic HAART-treated subjects at two different time points with at least 14 months between independent measurements (Fig. 5c). The size of the viral reservoir decreased very slowly with time in the eight aviremic subjects tested. We analyzed our data by using a previously described regression model39, and we found a mean half-life of this reservoir of 39.5 months, indicating that an average of 65.7 years of treatment would be necessary to eradicate 1 × 106 infected cells. Of note, we observed a significant negative correlation between this decrease and the percentage of proliferating TTM cells (P = 0.007, Fig. 5d). Moreover, we observed that plasma IL-7 concentrations inversely correlated with the decrease of the reservoir size over time (P = 0.037, Fig. 5e).

Altogether, these results indicate that IL-7 is responsible for the persistence of latently HIV-infected CD4+ T cells by promoting homeostatic proliferation of memory CD4+ T cells, resulting in the quantitative and qualitative stability of the HIV reservoir.

Cellular proliferation influences the HIV reservoir

We performed in vitro experiments to evaluate the relative impact of antigen-induced and homeostatic proliferation on the maintenance of the HIV reservoir. We stimulated CD4+ T cells from two virally suppressed subjects through TCR triggering (CD3 and CD28) or incubate them with IL-7 in the presence of zidovudine and ritonavir to avoid possible de novo infection of cells with HIV. We observed that TCR triggering induced modifications in the distribution of CD4+ T cell subset and was accompanied by high levels of proliferation (Fig. 6a,b). In contrast, IL-7 at 1 ng ml−1 and 10 ng ml−1 was able to induce proliferation of CD4+ T cells with limited impact on the distribution of the various naive and memory T cell subsets, confirming the homeostatic nature of the proliferation induced by this cytokine. Analysis of HIV sequences after IL-7 treatment indicated that this cytokine induced the proliferation of CD4+ T cells without modifying the diversity of the viral reservoir, as indicated by the absence of a significant difference in the genetic diversity of the proviral populations at baseline and after 8 d of culture (Fig. 6c). In contrast, CD4+ T cells treated with CD3 and CD28 showed a significant reduction in the diversity of the proviral population (subjects 1 and 2, P = 0.0002 and P < 0.0001, respectively). Of note, we used the same number of positive PCR reactions for cloning of proviral quasispecies under each experimental condition (n = 7), indicating that the decrease in viral genetic diversity is unlikely to be attributable exclusively to cell death. Thus, the decrease in the viral genetic diversity observed after TCR triggering is most probably attributable to the specific expansion of a small number of HIV-infected memory CD4+ T cell clones, which are undergoing substantial proliferation in our cultures at day 8, as indicated by increased frequencies of Ki67+ cells (Fig. 6b). This observation supports our findings in vivo showing that TCR-induced proliferation is responsible for the specific expansion of a restricted number of CD4+ T cell clones harboring a limited set of divergent HIV sequences (Fig. 5a). Thus, these results indicate that IL-7 can mediate the survival of HIV-infected cells through homeostatic proliferation, thereby ensuring the persistence of a genetically stable HIV reservoir, whereas antigen-induced proliferation leads to the genetic evolution of the proviral population through the preferential proliferation and survival of a restricted number of CD4+ T cell clones.

Figure 6
IL-7 induces homeostatic proliferation of CD4+ T cells and ensures HIV reservoir stability through cellular proliferation at low levels. (a) Phenotype of CD4+ T cells after TCR-induced (CD3/CD28) or IL-7 proliferation. Cells were harvested at day 8, and ...


We have identified two viral reservoirs within memory CD4+ T cell subsets of virally suppressed subjects. The TCM reservoir is the major long-lasting reservoir in immune responders to HAART. As TCM cells are characterized by their extremely low degree of cellular proliferation, and, because of their intrinsic capacity to survive for decades20,21, these cells provide a long-lasting cellular reservoir for HIV. In immune responders to HAART with normal CD4+ counts, the size of the HIV reservoir decreases very slowly with time, indicating that this cellular reservoir could be partially depleted through the use of intensive antiviral strategies for prolonged periods of time. The second reservoir is harbored by TTM cells and is the main reservoir in individuals with low CD4+ counts, the majority of whom are characterized by persistent immune activation. Our results clearly show that this reservoir persists by homeostatic proliferation of infected TTM cells, ensuring the stability of this viral reservoir in its size and its genetic variability. As the size of this TTM reservoir is reduced in individuals who have been treated early in infection, our findings confirm the importance of early therapeutic intervention, as it limits the size of this proliferating HIV reservoir8.

Several studies have clearly shown the continuous production of virions during HAART13,40,41; a recent analysis of longitudinal plasma samples suggests that this low-level, persistent viremia seems to arise from at least two cellular compartments, one in which viral production decays over time and a second that remains stable for at least 7 years42. Our identification of TCM cells and TTM cells as two major reservoirs that are characterized by differing decay rates in HAART-treated individuals supports these findings. Our observations also provide the first evidence, to our knowledge, for the validity of the mathematical model proposed recently, in which bystander proliferation of HIV-infected CD4+ T cells can ensure HIV reservoir persistence without any demonstrable evidence for viral production43.

The impact of viral production on the replenishment of the HIV reservoir is still controversial17,18,4446. A recent study concluded that persistence of the HIV reservoir is unlikely to result from ongoing viral replication, as sequences from the predominant plasma clones are different from those found in the proviral reservoir18. Moreover,genetic analysis of rebounding viruses after treatment interruptions argues against persistence of ongoing low-level replication in individuals on suppressive HAART47. Accordingly, our findings suggest a limited role for viral replication in the persistence of the reservoir. First, the nonstochastic distribution of HIV-infected cells among T cell subsets that are permissive to HIV infection suggests that de novo infection of CD4+ T cells does not occur. Second, HAART-treated individuals with high levels of immune activation, in whom ongoing replication is most likely to occur, do not show any evidence of genetic evolution in their proviral populations. Altogether, these observations strongly suggest that ongoing viral replication is unlikely to be responsible for the persistence of HIV-infected cells and strengthen the role of cell proliferation as a major mechanism to ensure HIV persistence.

IL-7 has been shown to induce the proliferation and survival of memory CD4+ T cells25. We found that CD4+ T cell depletion is accompanied by increased amounts of IL-7, which provides a potential mechanism by which latently infected CD4+ T cells could proliferate in response to this cytokine, as measured by Ki67 expression. Our results are in line with a recent study indicating that CD4+ T cell proliferation in HIV-infected individuals (as assessed by BrdU incorporation) is driven by IL-7 as a homeostatic response to CD4+ T cell depletion48. However, our Ki67 measurements may have over-estimated the frequency of dividing cells, as Ki67+ cells may not represent true in vivo proliferation in HIV-infected individuals, particularly in untreated subjects49,50. These results and our observations suggest that a quantitatively stable pool of memory CD4+ T cells that include cells with integrated HIV DNA is maintained through continuous proliferation and apoptosis at low levels in HAART-treated individuals with low CD4+ counts. Our longitudinal analysis shows that the stability of the HIV reservoir size and the conservation of viral sequences over time are associated with IL-7 concentrations in plasma. We observed here that IL-7 is able to induce homeostatic proliferation of CD4+ T cells in vitro, thereby ensuring the persistence of HIV proviral sequences. These observations show a role for IL-7 in the maintenance of latently infected CD4+ T cells through cytokine-induced homeostatic proliferation and survival.

Our results indicate that HIV persists in two reservoirs that are maintained by distinct mechanisms. Individuals who have started treatment early in infection carry a viral reservoir of limited size that is harbored mainly by TCM cells, which have the capacity to survive for long periods of time21,22. Although these cells that harbor archived proviral DNA are highly stable, the reservoir may decrease at a very slow rate as a consequence of the ability of these cells to mount antigen-induced responses, leading to the elimination of a fraction of infected cells through CTL killing, cytopathic effect and apoptosis during the contraction phase. The HIV reservoir is mainly retrieved in TTM cells in subjects with increased frequencies of proliferating CD4+ T cells because HAART treatment was initiated at a later stage of the disease. This subset of CD4+ T cells continuously proliferates at low levels, leading to the persistence of a genetically stable HIV reservoir through IL-7–induced mitosis of TTM cells. These results suggest that therapeutic strategies relying solely upon antiretroviral molecules will never reach the objective of viral eradication.

Finally, our results indicate that HIV proviral DNA is harbored by cells that express immune activation and proliferation markers such as PD-1 and Ki67. New therapies should target pathways downstream of homeostatic proliferation including inhibitors of the IL-7 pathway or pathways associated with self-renewal and `stem cell-ness', such as those developed for the treatment of leukemias and cancers51. Indeed, by limiting immune activation and affecting long-lived infected CD4+ T cells by targeting IL-7–dependent proliferation and the self-renewal of memory T cells in association with HAART, eradication of virus in aviremic individuals could become a more realistic endeavor.


Methods and any associated references are available in the online version of the paper at


We thank the study subjects for their participation in this study. We also thank M. Legault and C. Grignon for clinical assistance with subjects, N. Kettaf, M. Lainesse, V. Lafontaine and Y. Chouikh for technical assistance, S. Gimmig and L. Lejeune for flow cytometric cell sorting and T. Sing for assistance with the co-receptor prediction software. We are grateful to E. Hunter for his expertise in phylogenetic analyses. N.C. is supported by the American Foundation for AIDS Research (amfAR, fellowship number 106634-38-RFRL). M.E. and L.T. are funded by the Canadian Institutes of Health Research. J.P.R., is a clinician-scientist supported by Fonds de la Recherche en Santé du Québec (FRSQ). R.-P.S. is the Canada Research Chair in Human Immunology. This study was supported by funds from amfAR (grants 106-722-40-RGRL, 106-847-42-RGRL and 107-175-44-RGRL), CANFAR (grant 18008), the US National Institutes of Health, the Canadian Institutes of Health Research, the Canadian HIV Trials Network, Vaccines and Immunotherapeutics core and the Réseau FRSQ-SIDA/maladies infectieuses.


Accession codes. Sequences for Env genes have been deposited in GenBank with accession numbers EU700514 to EU700943.

Note: Supplementary information is available on the Nature Medicine website.

Reprints and permissions information is available online at

Supplementary Material

Supplemental data


1. Palella FJ, Jr., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 1998;338:853–860. [PubMed]
2. Finzi D, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278:1295–1300. [PubMed]
3. Chun TW, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA. 1997;94:13193–13197. [PubMed]
4. Chun TW, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997;387:183–188. [PubMed]
5. Finzi D, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 1999;5:512–517. [PubMed]
6. Hermankova M, et al. Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J. Virol. 2003;77:7383–7392. [PMC free article] [PubMed]
7. Chun TW, et al. Relationship between the size of the human immunodeficiency virus type 1 (HIV-1) reservoir in peripheral blood CD4+ T cells and CD4+:CD8+ T cell ratios in aviremic HIV-1–infected individuals receiving long-term highly active antiretroviral therapy. J. Infect. Dis. 2002;185:1672–1676. [PubMed]
8. Strain MC, et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J. Infect. Dis. 2005;191:1410–1418. [PubMed]
9. Plana M, et al. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. AIDS. 2000;14:1921–1933. [PubMed]
10. Anthony KB, et al. Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. J. Acquir. Immune Defic. Syndr. 2003;33:125–133. [PubMed]
11. Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino RM. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J. Immunol. 2002;169:3400–3406. [PubMed]
12. Chun TW, et al. Gene expression and viral production in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc. Natl. Acad. Sci. USA. 2003;100:1908–1913. [PubMed]
13. Persaud D, et al. Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J. Virol. 2004;78:968–979. [PMC free article] [PubMed]
14. Mens H, et al. Investigating signs of recent evolution in the pool of proviral HIV type 1 DNA during years of successful HAART. AIDS Res. Hum. Retroviruses. 2007;23:107–115. [PubMed]
15. Persaud D, et al. Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy. AIDS Res. Hum. Retroviruses. 2007;23:381–390. [PubMed]
16. Ruff CT, et al. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J. Virol. 2002;76:9481–9492. [PMC free article] [PubMed]
17. Kieffer TL, et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J. Infect. Dis. 2004;189:1452–1465. [PubMed]
18. Sedaghat AR, Siliciano JD, Brennan TP, Wilke CO, Siliciano RF. Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART. PLoS Pathog. 2007;3:e122. [PMC free article] [PubMed]
19. Hammarlund E, et al. Duration of antiviral immunity after smallpox vaccination. Nat. Med. 2003;9:1131–1137. [PubMed]
20. Combadiere B, et al. Distinct time effects of vaccination on long-term proliferative and IFN-γ-producing T cell memory to smallpox in humans. J. Exp. Med. 2004;199:1585–1593. [PMC free article] [PubMed]
21. Riou C, et al. Convergence of TCR and cytokine signaling leads to FOXO3a phosphorylation and drives the survival of CD4+ central memory T cells. J. Exp. Med. 2007;204:79–91. [PMC free article] [PubMed]
22. van Grevenynghe J, et al. Transcription factor FOXO3a controls the persistence of memory CD4+ T cells during HIV infection. Nat. Med. 2008;14:266–274. [PubMed]
23. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708–712. [PubMed]
24. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 2004;22:745–763. [PubMed]
25. Geginat J, Sallusto F, Lanzavecchia A. Cytokine-driven proliferation and differentiation of human naive, central memory and effector memory CD4+ T cells. Pathol. Biol. (Paris) 2003;51:64–66. [PubMed]
26. Napolitano LA, et al. Increased production of IL-7 accompanies HIV-1–mediated T-cell depletion: implications for T-cell homeostasis. Nat. Med. 2001;7:73–79. [PubMed]
27. Koelsch KK, et al. Dynamics of total, linear nonintegrated and integrated HIV-1 DNA in vivo and in vitro. J. Infect. Dis. 2008;197:411–419. [PubMed]
28. Kinter AL, et al. The common γ-chain cytokines IL-2, IL-7, IL-15 and IL-21 induce the expression of programmed death-1 and its ligands. J. Immunol. 2008;181:6738–6746. [PubMed]
29. Lin SJ, Peacock CD, Bahl K, Welsh RM. Programmed death-1 (PD-1) defines a transient and dysfunctional oligoclonal T cell population in acute homeostatic proliferation. J. Exp. Med. 2007;204:2321–2333. [PMC free article] [PubMed]
30. Hokey DA, et al. Activation drives PD-1 expression during vaccine-specific proliferation and following lentiviral infection in macaques. Eur. J. Immunol. 2008;38:1435–1445. [PMC free article] [PubMed]
31. Siddique MA, et al. Low CD4+ T cell nadir is an independent predictor of lower HIV-specific immune responses in chronically HIV-1-infected subjects receiving highly active antiretroviral therapy. J. Infect. Dis. 2006;194:661–665. [PubMed]
32. Younes SA, et al. The duration of exposure to HIV modulates the breadth and the magnitude of HIV-specific memory CD4+ T cells. J. Immunol. 2007;178:788–797. [PubMed]
33. Younes SA, et al. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J. Exp. Med. 2003;198:1909–1922. [PMC free article] [PubMed]
34. Fry TJ, et al. A potential role for interleukin-7 in T-cell homeostasis. Blood. 2001;97:2983–2990. [PubMed]
35. Llano A, et al. Interleukin-7 in plasma correlates with CD4 T-cell depletion and may be associated with emergence of syncytium-inducing variants in human immunodeficiency virus type 1-positive individuals. J. Virol. 2001;75:10319–10325. [PMC free article] [PubMed]
36. Mercier F, et al. Persistent human immunodeficiency virus-1 antigenaemia affects the expression of interleukin-7Rα on central and effector memory CD4+ and CD8+ T cell subsets. Clin. Exp. Immunol. 2008;152:72–80. [PubMed]
37. Seddon B, Tomlinson P, Zamoyska R. Interleukin 7 and T cell receptor signals regulate homeostasis of CD4 memory cells. Nat. Immunol. 2003;4:680–686. [PubMed]
38. Kondrack RM, et al. Interleukin 7 regulates the survival and generation of memory CD4 cells. J. Exp. Med. 2003;198:1797–1806. [PMC free article] [PubMed]
39. Siliciano JD, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 2003;9:727–728. [PubMed]
40. Zhang L, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 1999;340:1605–1613. [PubMed]
41. Dornadula G, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. J. Am. Med. Assoc. 1999;282:1627–1632. [PubMed]
42. Palmer S, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. USA. 2008;105:3879–3884. [PubMed]
43. Kim H, Perelson AS. Viral and latent reservoir persistence in HIV-1-infected patients on therapy. PLOS Comput. Biol. 2006;2:e135. [PubMed]
44. Chun TW, et al. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J. Clin. Invest. 2005;115:3250–3255. [PMC free article] [PubMed]
45. Tobin NH, et al. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J. Virol. 2005;79:9625–9634. [PMC free article] [PubMed]
46. Ramratnam B, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat. Med. 2000;6:82–85. [PubMed]
47. Joos B, et al. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc. Natl. Acad. Sci. USA. 2008;105:16725–16730. [PubMed]
48. Catalfamo M, et al. HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proc. Natl. Acad. Sci. USA. 2008;105:19851–19856. [PubMed]
49. Combadière B, et al. CD4+Ki67+ lymphocytes in HIV-infected patients are effector T cells accumulated in the G1 phase of the cell cycle. Eur. J. Immunol. 2000;30:3598–3603. [PubMed]
50. Sieg SF, Bazdar DA, Lederman MM. S-phase entry leads to cell death in circulating T cells from HIV-infected persons. J. Leukoc. Biol. 2008;83:1382–1387. [PMC free article] [PubMed]
51. Dick JE. Stem cell concepts renew cancer research. Blood. 2008;112:4793–4807. [PubMed]